Navigation Links
ChemoCentryx Completes Enrollment of PROTECT-1, a Phase II/III Clinical Trial of CCR9 Antagonist CCX282-B (Traficet-EN(TM)) in Crohn's Disease
Date:6/12/2008

ary efficacy endpoint in the induction phase of the study is the attainment of a clinical response defined as a decrease from baseline in the Crohn's Disease Activity Index (CDAI) score of at least 70 points. In a separate clinical trial, Traficet-EN is also being evaluated for patients with celiac disease, a sensitivity to gluten and gluten derivatives in which digestive tract T cells are thought to play an important role.

"We are very pleased to have completed enrollment of more than 430 patients for the PROTECT-1 study at clinical sites in 17 countries worldwide. This represents an important milestone in the development of this promising new drug, as well as an impressive accomplishment by a committed group of investigators throughout the world and our entire clinical team," said Pirow Bekker, M.D., Ph.D., Vice President, Medical and Clinical Affairs of ChemoCentryx. "Following completion of PROTECT-1, our goal is to expeditiously advance additional clinical development of Traficet-EN to support regulatory filings worldwide."

ChemoCentryx's Second-Generation CCR9 Program

ChemoCentryx is also advancing a second-generation, orally-active CCR9 antagonist through preclinical development and anticipates a regulatory filing to enable first-in-human studies on this compound in the second half of the year. Structurally diverse from Traficet-EN, this second-generation CCR9 antagonist strengthens ChemoCentryx's proprietary position in the CCR9 arena, and gives the company the potential to pursue additional gastrointestinal and other clinical indications with discrete compounds.

The CCR9 program is a part of a strategic alliance that ChemoCentryx signed in 2006 with GlaxoSmithKline's Center of Excellence for External Drug Discovery (CEEDD) for the discovery and development of small molecule antagonists targeting four defined chemokine and chemoattractant receptors. Under the terms of the agreement, ChemoCentryx is responsible for advancing produc
'/>"/>

SOURCE ChemoCentryx, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. ChemoCentryx Initiates Clinical Trial of CCR1 Inhibitor CCX354
2. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
5. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
6. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
7. QuatRx Completes Patient Enrollment in Phase 3 Study of Ophena(TM) in Women with Postmenopausal Vaginal Syndrome
8. CryoCor Completes Enrollment of Pivotal Clinical Study for Atrial Fibrillation
9. Anesiva Completes Enrollment in Phase 3 Clinical Trial of Zingo(TM) to Treat Pain Associated With Venous Access Procedures in Adults
10. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
11. Cadence Pharmaceuticals Completes Enrollment of Pivotal Phase III Trial for Intravenous Acetaminophen Ahead of Schedule
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... July 24, 2014   Royal Philips (NYSE: ... it has received 510(k) clearance from the U.S. Food ... ultrasound system, VISIQ, in the U.S. VISIQ ... benefits of greater mobility, performance and simplicity into a ... diagnostic scans for more OB patients. This ...
(Date:7/24/2014)... Texas , July 24, 2014  To ... the cardiovascular market that could impact patient care ... Spring 2014 CV Watch , "Innovations in Cardiovascular ... provides hospitals with guidance and details on promising ... patient needs and understand how these options impact ...
(Date:7/24/2014)... Second Quarter and Recent Highlights: , ... effective September 2, 2014 , Product revenues grew ... ® revenues grew 14 percent year-over-year to $15.3 ... percent year-over-year to $1.1 million , HeRO ® ... million , Tissue processing revenues decreased 6 percent ...
Breaking Medicine Technology:Philips receives FDA 510(k) clearance for its innovative ultra mobile VISIQ ultrasound system 2Philips receives FDA 510(k) clearance for its innovative ultra mobile VISIQ ultrasound system 3New Novation CV Watch Shows Recent Technology Innovations Could Drive Cardiovascular Product Costs Up by as Much as 35 Percent 2New Novation CV Watch Shows Recent Technology Innovations Could Drive Cardiovascular Product Costs Up by as Much as 35 Percent 3CryoLife Second Quarter 2014 Revenues Increase 3 Percent to a Record $34.7 Million 2CryoLife Second Quarter 2014 Revenues Increase 3 Percent to a Record $34.7 Million 3CryoLife Second Quarter 2014 Revenues Increase 3 Percent to a Record $34.7 Million 4CryoLife Second Quarter 2014 Revenues Increase 3 Percent to a Record $34.7 Million 5CryoLife Second Quarter 2014 Revenues Increase 3 Percent to a Record $34.7 Million 6CryoLife Second Quarter 2014 Revenues Increase 3 Percent to a Record $34.7 Million 7CryoLife Second Quarter 2014 Revenues Increase 3 Percent to a Record $34.7 Million 8CryoLife Second Quarter 2014 Revenues Increase 3 Percent to a Record $34.7 Million 9CryoLife Second Quarter 2014 Revenues Increase 3 Percent to a Record $34.7 Million 10CryoLife Second Quarter 2014 Revenues Increase 3 Percent to a Record $34.7 Million 11CryoLife Second Quarter 2014 Revenues Increase 3 Percent to a Record $34.7 Million 12CryoLife Second Quarter 2014 Revenues Increase 3 Percent to a Record $34.7 Million 13CryoLife Second Quarter 2014 Revenues Increase 3 Percent to a Record $34.7 Million 14CryoLife Second Quarter 2014 Revenues Increase 3 Percent to a Record $34.7 Million 15CryoLife Second Quarter 2014 Revenues Increase 3 Percent to a Record $34.7 Million 16CryoLife Second Quarter 2014 Revenues Increase 3 Percent to a Record $34.7 Million 17
... , WASHINGTON, Dec. 18 John Kopchinski, ... successful, record-setting "qui tam" case against Pfizer Inc. , ... ethics for 2009. , Ethisphere, a think tank that ... compiles an annual list of the 100 most influential ...
... , INDIANAPOLIS, Dec. 18 Eli Lilly and Company (NYSE: ... vice president and chief financial officer for Lilly, has assumed ... global services and chief financial officer, effective January 1. ... chief financial officer of the company and add responsibility for ...
Cached Medicine Technology:Pfizer Whistleblower Named Year's Most Influential Person In Business Ethics 2Lilly CFO Derica Rice Assumes Expanded Responsibilities, Promoted to Executive Vice President 2
(Date:7/24/2014)... CA (PRWEB) July 24, 2014 On October ... ones will descend upon the Embassy Suites LAX North for ... hosted by DiabetesSisters and the first time it has convened ... time for the organization to open the entire event to ... the only conference of its kind worldwide for women with ...
(Date:7/24/2014)... July 24, 2014 (HealthDay News) -- A new formulation ... from snorting or injecting the drug has been approved ... Targiniq ER and made by Purdue Pharma, the pill ... a drug that blocks the euphoric effects of oxycodone. ... crushed, snorted, dissolved or injected, according to the FDA. ...
(Date:7/24/2014)... 24, 2014 Skirt Sports, the innovative women’s ... of the running skirt. Born from an idea by professional ... an Ironman race in 2004, this one innovative piece of ... prize money from her victory in Wisconsin to incorporate Skirt ... specific athletic skirts. , “When I drew the first sketch ...
(Date:7/24/2014)... July 24, 2014 The North American Omega ... omega 3 & structured lipids market in North America with ... is estimated to grow from around $762.4 million in 2012 ... from 2013 to 2018. , Browse through the TOC of ... to get an idea of the in-depth analysis provided. This ...
(Date:7/24/2014)... (PRWEB) July 24, 2014 The ... to announce a new distribution agreement with game ... collaboration between the two groups to offer ... clinicians using biofeedback and neurofeedback in European and ... “video game” developed expressly to be used as ...
Breaking Medicine News(10 mins):Health News:DiabetesSisters Brings Conference for Women with Diabetes Los Angeles for the First Time 2Health News:DiabetesSisters Brings Conference for Women with Diabetes Los Angeles for the First Time 3Health News:FDA Approves Hard-to-Abuse Narcotic Painkiller 2Health News:Skirt Sports Celebrates Its 10-Year Anniversary and 10 Years of the Running Skirt With a Virtual Community Building Run 2Health News:Skirt Sports Celebrates Its 10-Year Anniversary and 10 Years of the Running Skirt With a Virtual Community Building Run 3Health News:North America Omega 3 & Structured Lipids (Nutraceuticals) Market is Expected to Reach $1,117 million in 2018 - New Report by MicroMarket Monitor 2Health News:North America Omega 3 & Structured Lipids (Nutraceuticals) Market is Expected to Reach $1,117 million in 2018 - New Report by MicroMarket Monitor 3Health News:North America Omega 3 & Structured Lipids (Nutraceuticals) Market is Expected to Reach $1,117 million in 2018 - New Report by MicroMarket Monitor 4Health News:North America Omega 3 & Structured Lipids (Nutraceuticals) Market is Expected to Reach $1,117 million in 2018 - New Report by MicroMarket Monitor 5Health News:Biofeedback Federation of Europe Enters Distribution Agreement with Zukor Interactive 2Health News:Biofeedback Federation of Europe Enters Distribution Agreement with Zukor Interactive 3
... are seeing the first signs of a reverse brain ... grow over time. The emergence of modern,corporate and investorowned ... NRI doctors back to home turf. ,And unlike other ... the main draw, doctors are actually taking pay cuts ...
... together will build the worlds first "all digital ... by the out patient surgical rehabilitation chain. The ... screens connected to the Internet, electronic medical records ... permitting doctors and other caregivers to access patients' ...
... in the United States of America, says that children suffer ... an unhappy marriage and avoid a divorce for the sake ... only do more damage to the kids, the authors of ... of Pennsylvania State University in University Park conducted the exhaustive ...
... giants has just begun. After waging wars over many drug ... treatment. The ball was set in motion by the dramatic ... AIDS treatment would cost less than a U.S. dollar a ... announced plans of its own production of anti retroviral drugs ...
... humour. It stirred up a controversy. Now it is being ... officially announced that the advertisement in question might not be ... they did not enjoy the advertisement poking fun at organ ... a carousel horse. A team of medics approaches him and ...
... the tedious process of finding survivors of the Gujarat quake, from ... more survivors. They are now concentrating in clearing the rubble and ... far. A miracle baby was saved after nearly 90 hours under ... holding on to the dead body of its mother. The baby ...
Cached Medicine News:Health News:Lure of the home turf brings back NRI doctors 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: